Gavi, the Vaccine Alliance announced that it had signed an advance purchase agreement with Novavax for its highly efficacious NVX-CoV2373 vaccine candidate against COVID-19. The agreement is for a commitment to purchase 350 million doses of the Novavax vaccine candidate, secured on behalf of the COVAX Facility.
Supply of the vaccine is anticipated to commence in Q3 2021, as soon as Novavax has secured the required regulatory approvals. Deliveries would then continue through the second half of the year and into 2022.
Dr Seth Berkley, CEO of Gavi said, “This agreement with Novavax marks a major step towards COVAX’s objective of building the world’s largest and most diverse portfolio of COVID-19 vaccines, and a major step towards our goal of delivering 2 billion doses of safe and effective vaccines in 2021. Novavax’s commitment not only to support COVAX directly but also through technology transfer via other manufacturers, shines a light on the end-to-end nature of COVAX and the kind of collaboration needed to bring this pandemic under control.”
The Novavax vaccine will be used to supply both high-income and upper middle-income self-financing participants in the COVAX Facility, as well as the 92 lower-income economies eligible for donor-funded doses via the Gavi COVAX Advance Market Commitment (AMC). In order to anticipate the rising threat of variants, the agreement also contains the opportunity to access variant-adapted vaccine if this becomes necessary.
NVX-CoV2373 is part of the COVAX R&D portfolio, and the development and manufacturing of the vaccine have been accelerated by significant investments by COVAX co-lead the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI’s investments were directly linked to equitable access commitments which have been key to enabling this agreement, including providing COVAX with priority access to production from the CEPI-funded manufacturing network for Novavax.
Dr Richard Hatchett, CEO of CEPI said, “CEPI’s investments to accelerate the clinical development and manufacturing of this vaccine candidate have been critical to enabling equitable access to the vaccine through COVAX. With this agreement in place, the Novavax vaccine candidate will play a vital role in our mission to protect those most at risk from COVID-19, wherever they are in the world.”
The COVAX Facility portfolio, administered by Gavi, currently consists of agreements related to 8 vaccines and vaccine candidates – AstraZeneca/Oxford, Pfizer-BioNTech, Moderna, Novavax, Johnson & Johnson, SII-Covishield, SII-Covovax, and Sanofi/GSK. A further 7 vaccine candidates are supported by the COVAX R&D portfolio, administered by CEPI.